

Availability of Transgene's 2025 Universal Registration Document (URD)

Strasbourg, April 9, 2026, 6:00 pm CET

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its **2025 Universal Registration Document** was filed with the **French Financial Markets Authority (Autorité des marchés financiers – AMF)** on April 9, 2026, under number D.26-0241.

This document, available on the AMF's website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene's website (www.transgene.com).

It includes the following documents:

- the Annual Financial Report;
- the Board of Directors' Corporate Governance Report;
- the Statutory Auditors' Reports;
- information on the Company's share capital, including the share buyback program;
- information on the Statutory Auditors' fees.

The Universal Registration Document also includes information on the Company's Environmental, Social and Governance (ESG) factors.